Evidence map›Paper›PMID 40188059›Full record

Observational studyBMC cardiovascular disorders2025

The prognostic value of HFA-PEFF score in connective tissue disease-associated PAH: evidence from a cohort study.

Jiayi Dai, Li Ma, Yixin Zhang, Linwei Shan, Dongyu Li, Lin Li, Qi Hu, Zhangdi Zhou, Xiaoxuan Sun, Qiang Wang and 1 more

Registry-linked trialAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05980728 (The Prognostic Value of Biomarker in Connective Tissue Disease Patients With Pulmonary Hypertension), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05980728 not yet recruitingnot on this map

The Prognostic Value of Biomarker in Connective Tissue Disease Patients With Pulmonary Hypertension

Typeobservational_patient_registrySponsorThe First Affiliated Hospital with Nanjing Medical UniversityRan2023 to 2030Enrolled500ConditionsConnective Tissue Diseases, Pulmonary HypertensionArmsNo Intervention
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jiayi Dai *The Department of Cardiology, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province, No.300 Guangzhou Road, Nanjing, 210029, People's Republic of China.
Li Ma *Jiangsu Joint Institude of Health, the Friendship Hospital of Ili Kazakh Autonomous Prefecture, Uyghur Autonomous Region, No.92 Stalin Street, Yining, Xinjiang, 839300, People's Republic of China.
Yixin Zhang *The Department of Cardiology, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province, No.300 Guangzhou Road, Nanjing, 210029, People's Republic of China.
Linwei ShanThe Department of Cardiology, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province, No.300 Guangzhou Road, Nanjing, 210029, People's Republic of China.
Dongyu LiThe Department of Rheumatology, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province, No.300 Guangzhou Road, Nanjing, 210029, People's Republic of China.
Lin LiThe Department of Cardiology, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province, No.300 Guangzhou Road, Nanjing, 210029, People's Republic of China.
Qi HuThe Department of Cardiology, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province, No.300 Guangzhou Road, Nanjing, 210029, People's Republic of China.
Zhangdi ZhouThe Department of Rheumatology, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province, No.300 Guangzhou Road, Nanjing, 210029, People's Republic of China.
Xiaoxuan SunThe Department of Rheumatology, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province, No.300 Guangzhou Road, Nanjing, 210029, People's Republic of China.
Qiang Wang *The Department of Rheumatology, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province, No.300 Guangzhou Road, Nanjing, 210029, People's Republic of China.
Lei Zhou *The Department of Geriatric Cardiology, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province, No.300 Guangzhou Road, Nanjing, 210029, People's Republic of China. zhoulei@njmu.edu.cn.

Funding

Regional Key Research Project of Ili Kazakh Autonomous Prefecture yl2021zd02The National Natural Science Foundation of China 82370897
6 · The paper itself

Abstract

backgroundConnective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) patients with left heart dysfunction may have worse prognosis. This study was to investigate the prognostic value of HFA-PEFF score in connective tissue disease-associated PAH.

methodsThis single-center retrospective cohort study enrolled 147 CTD-PAH patients diagnosed via right heart catheterization (RHC), divided into two groups based on their HFA-PEFF scores: < 5 (n = 74) and ≥ 5 (n = 73). The clinical characteristics were compared between the two groups. The primary end point was all-cause mortality, and the secondary end point was clinical worsening events. Survival was analyzed using Kaplan-Meier analysis and Cox proportional hazards models.

resultsCompared to the HFA-PEFF score < 5 group, the ≥ 5 group exhibited significantly higher levels of N-terminal pro-brain natriuretic peptide (NT-proBNP), a greater proportion of WHO functional class III-IV, shorter 6-min walk distance (6MWD), larger right ventricular (RV) volume, worse RV function, smaller left ventricular (LV) volume, and higher native T1 values. An HFA-PEFF score ≥ 5 was a predictor for all-cause mortality in CTD-PAH (HR 5.022, P = 0.020) and for clinical worsening events (HR 2.670, P = 0.020). At follow-up, 17.9% of CTD-PAH had an HFA-PEFF score ≥ 5. Patients with follow-up HFA-PEFF scores ≥ 5 had a significantly lower event-free survival rate (P < 0.001).

conclusionAn HFA-PEFF score ≥ 5 was associated with all-cause mortality and clinical worsening events in CTD-PAH patients.

trial registrationNCT05980728. Connective Tissue Disease Patients With Pulmonary Hypertension. Oct 17, 2023.

Indexed as

Arterial PressureConnective Tissue DiseasesPulmonary Arterial HypertensionVentricular Dysfunction, LeftVentricular Function, LeftVentricular Function, RightAdultAgedBiomarkersCardiac CatheterizationDisease ProgressionFemaleHumansMaleMiddle AgedNatriuretic Peptide, BrainBiomarkersNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)All-cause mortalityClinical worsening eventsConnective tissue disease (CTD)HFA-PEFF scorePulmonary arterial hypertension (PAH)

Identifiers

PMID40188059
PMCPMC11972524

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.